Lv1
10 积分 2024-06-30 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1小时前
待确认
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
1天前
已完结
Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab
22天前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
6个月前
已完结
皖公网安备34019202002308
